Fluidigm (NASDAQ: FLDM) and Coherent (NASDAQ:COHR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.
This table compares Fluidigm and Coherent’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Fluidigm has a beta of 2.99, meaning that its share price is 199% more volatile than the S&P 500. Comparatively, Coherent has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
Earnings & Valuation
This table compares Fluidigm and Coherent’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fluidigm||$101.94 million||2.36||-$60.53 million||($1.19)||-5.22|
|Coherent||$1.72 billion||2.50||$207.12 million||$12.57||13.83|
Coherent has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Coherent, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
94.6% of Fluidigm shares are held by institutional investors. Comparatively, 98.4% of Coherent shares are held by institutional investors. 4.7% of Fluidigm shares are held by company insiders. Comparatively, 1.4% of Coherent shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of current recommendations for Fluidigm and Coherent, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fluidigm presently has a consensus price target of $6.10, indicating a potential downside of 1.77%. Coherent has a consensus price target of $296.63, indicating a potential upside of 70.59%. Given Coherent’s stronger consensus rating and higher possible upside, analysts clearly believe Coherent is more favorable than Fluidigm.
Coherent beats Fluidigm on 11 of the 13 factors compared between the two stocks.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Coherent, Inc. provides lasers and laser-based technology in a range of scientific, commercial, and industrial applications worldwide. It operates through two segments, Specialty Lasers and Systems, and Commercial Lasers and Components. The company designs, manufactures, services, and markets lasers, laser tools, precision optics, and related accessories. Its products are used in markets, such as microelectronics, materials processing, original equipment manufacturer components and instrumentation, and scientific research and government programs. The company markets its products through a direct sales force in the United States, as well as through direct sales personnel and independent representatives internationally. Coherent Inc. was founded in 1966 and is headquartered in Santa Clara, California.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.